Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8200MR)

This product GTTS-WQ8200MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8200MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5601MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ3872MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ10394MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ4855MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ4224MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ12136MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ4993MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ6547MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA D2E7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW